Clinical Outcomes with Alternative Dosing Strategies for Piperacillin/tazobactam: a Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Jan 10

PMID 25575030

Citations 22

Authors

Hui Yang

Chao Zhang

Quanyu Zhou

Yike Wang

Lujia Chen

Affiliations

Soon will be listed here.

Abstract

Objectives: A better dosing strategy can improve clinical outcomes for patients. We sought to compare the extended or continuous infusion with conventional intermittent infusion of piperacillin/tazobactam, investigating which approach is better and worthy of recommendation for clinical use.

Methods: Articles were gathered from PubMed, Web of Science, ProQuest, Science Direct, Cochrane, two Chinese literature databases (CNKI, Wan Fang Data) and related ICAAC and ACCP conferences. Randomized controlled and observational studies that compared extended or continuous infusion with conventional intermittent infusion of piperacillin/tazobactam were identified from the databases above and analyzed. Two reviewers independently extracted and investigated the data. A meta-analysis was performed using Revman 5.2 software. The quality of each study was assessed. Sensitivity analysis and publication bias were evaluated.

Results: Five randomized controlled trials and nine observational studies were included in this study. All included studies had high quality and no publication bias was found. Compared to the conventional intermittent infusion approach, the extended or continuous infusion group had a significantly higher clinical cure rate (OR 1.88, 95% CI 1.29-2.73, P = 0.0009) and a lower mortality rate (OR 0.67, 95% CI 0.50-0.89, P = 0.005). No statistical difference was observed for bacteriologic cure (OR 1.40, 95% CI 0.82-2.37, P = 0.22) between the two dosing regimens. The sensitivity analysis showed the results were stable.

Conclusions: Our systematic review and meta-analysis suggested that the extended or continuous infusion strategy of piperacillin/tazobactam should be recommended for clinical use considering its higher clinical cure rate and lower mortality rate in comparison with conventional intermittent strategy. Data from this study could be extrapolated for other β-lactam antimicrobials. Therefore, this dosing strategy could be considered in clinical practice.

Citing Articles

Interprofessional Therapeutic Drug Monitoring of Piperacillin/Tazobactam Enhances Care for Patients with Acute-on-Chronic Liver Failure in the ICU: A Retrospective Observational Pilot Study.

Schmid S, Zimmermann K, Koch C, Mester P, Athanasoulas G, Buttenschoen J Antibiotics (Basel). 2025; 14(2).

PMID: 40001445 PMC: 11851559. DOI: 10.3390/antibiotics14020202.

Antibiotic Prophylaxis in Patients Undergoing Lung Transplant: Single-Center Cohort Study.

Pascale R, Tazza B, Amicucci A, Salvaterra E, Dolci G, Antonacci F Transpl Int. 2024; 37:13245.

PMID: 39220301 PMC: 11361928. DOI: 10.3389/ti.2024.13245.

Intra-abdominal infections survival guide: a position statement by the Global Alliance For Infections In Surgery.

Sartelli M, Barie P, Agnoletti V, Al-Hasan M, Ansaloni L, Biffl W World J Emerg Surg. 2024; 19(1):22.

PMID: 38851700 PMC: 11161965. DOI: 10.1186/s13017-024-00552-9.

Problematic meta-analyses: Bayesian and frequentist perspectives on combining randomized controlled trials and non-randomized studies.

Moran J, Linden A BMC Med Res Methodol. 2024; 24(1):99.

PMID: 38678213 PMC: 11056075. DOI: 10.1186/s12874-024-02215-4.

Mortality of continuous infusion versus intermittent bolus of meropenem: a systematic review and meta-analysis of randomized controlled trials.

Ai M, Chang W, Liu C Front Microbiol. 2024; 15:1337570.

PMID: 38525074 PMC: 10957759. DOI: 10.3389/fmicb.2024.1337570.

References

Papich M . Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs. Vet Microbiol. 2014; 171(3-4):480-6. DOI: 10.1016/j.vetmic.2013.12.021. View

De Waele J, Carrette S, Carlier M, Stove V, Boelens J, Claeys G . Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2013; 40(3):380-7. DOI: 10.1007/s00134-013-3187-2. View

Yoon Y, Koob M . Transformation of isolated mammalian mitochondria by bacterial conjugation. Nucleic Acids Res. 2005; 33(16):e139. PMC: 1201378. DOI: 10.1093/nar/gni140. View

Kasiakou S, Lawrence K, Choulis N, Falagas M . Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs. 2005; 65(17):2499-511. DOI: 10.2165/00003495-200565170-00006. View

Nelson E . Critical appraisal. 5. Randomised controlled trials: questions for valid evidence. NT Learn Curve. 2000; 3(5):6-8. View

Villar J, Mackey M, Carroli G, Donner A . Meta-analyses in systematic reviews of randomized controlled trials in perinatal medicine: comparison of fixed and random effects models. Stat Med. 2001; 20(23):3635-47. DOI: 10.1002/sim.1096. View

Grant E, Kuti J, Nicolau D, Nightingale C, Quintiliani R . Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy. 2002; 22(4):471-83. DOI: 10.1592/phco.22.7.471.33665. View

Drusano G . Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003; 36(Suppl 1):S42-50. DOI: 10.1086/344653. View

Austin P, Alter D, Tu J . The use of fixed- and random-effects models for classifying hospitals as mortality outliers: a Monte Carlo assessment. Med Decis Making. 2003; 23(6):526-39. DOI: 10.1177/0272989X03258443. View

10.

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

11.

Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein U, Locker G . Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother. 1999; 43(4):523-7. DOI: 10.1093/jac/43.4.523. View

12.

Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar W . Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents. 2004; 25(1):62-7. DOI: 10.1016/j.ijantimicag.2004.08.012. View

13.

Li C, Kuti J, Nightingale C, Mansfield D, Dana A, Nicolau D . Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother. 2005; 56(2):388-95. DOI: 10.1093/jac/dki243. View

14.

Javad A, Vahid P, Kazem G, Alireza S, Gholamali G, Qulamreza K . Piperacillin/tazobactam in treatment of brain abscess. Scand J Infect Dis. 2006; 38(3):224-6. DOI: 10.1080/00365540500348978. View

15.

DeRyke C, Kuti J, Mansfield D, Dana A, Nicolau D . Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection. Am J Health Syst Pharm. 2006; 63(8):750-5. DOI: 10.2146/ajhp050323. View

16.

Rafati M, Rouini M, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K . Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents. 2006; 28(2):122-7. DOI: 10.1016/j.ijantimicag.2006.02.020. View

17.

Lodise T, Lomaestro B, Drusano G . Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006; 26(9):1320-32. DOI: 10.1592/phco.26.9.1320. View

18.

Lau W, Mercer D, Itani K, Nicolau D, Kuti J, Mansfield D . Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2006; 50(11):3556-61. PMC: 1635208. DOI: 10.1128/AAC.00329-06. View

19.

Lodise Jr T, Lomaestro B, Drusano G . Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007; 44(3):357-63. DOI: 10.1086/510590. View

20.

Roberts J, Paratz J, Paratz E, Krueger W, Lipman J . Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007; 30(1):11-8. DOI: 10.1016/j.ijantimicag.2007.02.002. View